Gastroesophageal junction adenocarcinoma

This study tests a combination of two drugs, abemaciclib and ramucirumab, in people with advanced esophageal or gastroesophageal junction cancer that has spread. The goal is to see if this treatment is safe and can help control tumor growth. About 8 participants are enrolled, and…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…

This trial tests an experimental drug called zanidatamab, which targets HER2, a protein that fuels certain breast and stomach cancers. Researchers give zanidatamab alongside chemotherapy, and sometimes with the immunotherapy tislelizumab, to people with advanced HER2-positive bre…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard trastuzumab plus chemotherapy could improve outcomes for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study enrolled 738 participants …

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer …

This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…

This trial tests whether adding the immunotherapy drug toripalimab to a standard chemotherapy regimen (FLOT) before surgery can improve outcomes for people with locally advanced gastric cancer. Participants receive four cycles of the combination, then undergo surgery, and are fol…

This phase II trial tests whether adding pembrolizumab (Keytruda) and trastuzumab (Ontruzant) to standard FLOT chemotherapy, given before and after surgery, can improve outcomes for people with HER2-positive esophagogastric adenocarcinoma. Participants receive the drug combinatio…

This phase 2 trial is testing whether a combination of three FDA-approved drugs—oxaliplatin, capecitabine (Xeloda), and cetuximab—can slow tumor growth in people with advanced or metastatic gastric or gastroesophageal cancer that has not been treated with chemotherapy before. The…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…

This phase 3 trial tests whether adding radiation to chemotherapy before surgery helps people with a certain type of stomach-esophagus cancer live longer without the disease returning. About 342 adults with locally advanced but potentially removable cancer will receive either che…

This study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participan…

This study tests whether giving a three-part treatment before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment combines an immunotherapy drug (tislelizumab) with standard chemotherapy and a short course of ra…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…

This phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …

This phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…

This phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …

This phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…

This study tested a new drug called gentuximab combined with the chemotherapy drug paclitaxel in 76 people with advanced stomach or gastroesophageal junction cancer that had worsened after initial treatment. The goal was to find a safe and effective dose and see if the combinatio…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This phase 2 trial tested a two-step treatment for advanced esophageal cancer that has a specific genetic marker (MGMT deficiency) and has stopped responding to standard chemotherapy. First, patients took a daily oral chemotherapy drug (temozolomide) for three months. Then, they …

This pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…

This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…

This study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) helps shrink stomach cancer before surgery and prevent it from coming back. 67 adults with resectable stomach or gastroesophageal junction cancer received the combination before …

This study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…

This early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to …

This phase 2 trial tested adding the immunotherapy drug durvalumab to a standard chemotherapy regimen (docetaxel, oxaliplatin, S-1) before and after surgery in 68 patients with resectable stomach or gastroesophageal junction cancer. The main goal was to see how many patients had …

This phase II study tested whether adding trastuzumab (a targeted therapy) to standard chemotherapy could help people with advanced stomach or gastroesophageal junction cancer. Unlike typical patients, these participants had tumors that tested negative for HER2 in tissue but posi…

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This study compared two chemotherapy regimens (FOLFOX and CarboP-pacliT) given with radiation before surgery for esophageal or junction cancer. 106 patients were enrolled to see which treatment leads to better tumor removal and fewer serious complications. The goal is to help doc…

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help pa…

This large Phase 3 trial tested adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy for people with advanced stomach cancer that cannot be removed by surgery. Over 1,500 participants received either pembrolizumab plus chemo or a placebo plus chemo. The…

This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants h…

This study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…

This study tested a drug called sacituzumab-govitecan in 58 people with advanced stomach cancer that had spread to other parts of the body. The drug targets a protein on cancer cells to deliver chemotherapy directly. The goal was to see if the drug could shrink tumors or slow the…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…

This study tested whether adding radiation to chemotherapy before surgery improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 204 adults with operable tumors received either chemotherapy alone or chemotherapy plus radiation before…

This study tested a combination of the immunotherapy drug tislelizumab and chemotherapy (XELOX) given before surgery to 28 people with locally advanced stomach or gastroesophageal junction cancer. The goal was to see if this approach could shrink tumors more effectively and be sa…

This study tested whether the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back after surgery. About 794 people who had surgery for stage II or III cancer of the esophagus or gastroesophageal junction received either nivolumab or a placebo. The main…

This phase 3 trial tested whether adding an immunotherapy drug called AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 610 participants received either AK104 plus chemo or a placebo plus chemo. The study is c…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer. The goal was to see if FAPI scans are more accurate than standard scans for determining the cancer stage before and after chemotherapy. By comparing scan results with t…

This phase II trial tested a concentrated plant dietary supplement (made from foods like taro, rice, and carrots) in 30 people with gastrointestinal cancers who had diarrhea from chemotherapy. Participants received the supplement alongside standard anti-diarrheal treatment. The g…

This study explores whether a special PET/MRI scan can predict how well esophageal cancer responds to chemotherapy and radiation given before surgery. Researchers will scan 121 patients during treatment and compare the images with the actual tumor response seen after surgery. The…

This trial tests whether an early PET scan can help doctors choose the right treatment for people with locally advanced oesophago-gastric cancer. Patients receive one round of standard chemotherapy, then a second PET scan. If the tumor shows a strong response, they continue chemo…

This study analyzed data from nearly 3,000 patients who had surgery for esophageal cancer between 2000 and 2010. Researchers looked at factors like patient health, treatment approach, and surgical technique to see what influences cancer recurrence and survival. The goal is to bet…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This study analyzed blood and tumor tissue samples from 28 people with stomach cancer to find biological markers that predict how well immunotherapy (tislelizumab) combined with chemotherapy works before surgery. The goal was to build a model that uses RNA and other factors to fo…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …